Validity of self-reported misuse of prescription opioid analgesics

Meredith Smith; Andrew Rosenblum; Mark Parrino; Chunki Fong; Salvatore Colucci

doi:10.3109/10826081003682107

Validity of self-reported misuse of prescription opioid analgesics

Meredith Smith
, Andrew Rosenblum
, Mark Parrino
, Chunki Fong
, Salvatore Colucci

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Aim: To determine concurrent validity of self-reported misuse of prescription opioids. Design and Setting: Cross-sectional study in five U.S. methadone maintenance programs. Participants: 92 addicts. Measurements: Self-reported questionnaire assessing past-month misuse of 14 opioid analgesics, and color photographs of five opioid analgesics with instructions to mark those used in the past month "to get high." Concordance between self-report and photograph endorsement was assessed via Kappa statistic. Findings: 29 respondents completed both questionnaire and photograph endorsements. Kappas were 0.62 (OxyContin®), 0.59 (methadone), 0.49 (Dilaudid®), and 0.46 (generic extended-release oxycodone). Conclusions: Good-to-fair concurrent validity of self-reported abuse was seen for OxyContin®, methadone, Dilaudid®, and generic extended-release oxycodone.

Original language	English
Pages (from-to)	1509-1524
Number of pages	16
Journal	Substance Use and Misuse
Volume	45
Issue number	10
DOIs	https://doi.org/10.3109/10826081003682107
State	Published - Jun 2010
Externally published	Yes

Keywords

Dilaudid®
Opioid analgesic abuse
OxyContin®
Self-reported drug misuse
Validity

Access to Document

10.3109/10826081003682107

Cite this

@article{9dcf82b817a241e08a86026568c6efa9,

title = "Validity of self-reported misuse of prescription opioid analgesics",

abstract = "Aim: To determine concurrent validity of self-reported misuse of prescription opioids. Design and Setting: Cross-sectional study in five U.S. methadone maintenance programs. Participants: 92 addicts. Measurements: Self-reported questionnaire assessing past-month misuse of 14 opioid analgesics, and color photographs of five opioid analgesics with instructions to mark those used in the past month {"}to get high.{"} Concordance between self-report and photograph endorsement was assessed via Kappa statistic. Findings: 29 respondents completed both questionnaire and photograph endorsements. Kappas were 0.62 (OxyContin{\textregistered}), 0.59 (methadone), 0.49 (Dilaudid{\textregistered}), and 0.46 (generic extended-release oxycodone). Conclusions: Good-to-fair concurrent validity of self-reported abuse was seen for OxyContin{\textregistered}, methadone, Dilaudid{\textregistered}, and generic extended-release oxycodone.",

keywords = "Dilaudid{\textregistered}, Opioid analgesic abuse, OxyContin{\textregistered}, Self-reported drug misuse, Validity",

author = "Meredith Smith and Andrew Rosenblum and Mark Parrino and Chunki Fong and Salvatore Colucci",

note = "Funding Information: Meredith Smith is Senior Scientific Director, Risk Man-agement for Pain Care and Immunology Development at Abbott Laboratories. Previously, Dr. Smith was at Purdue Pharma L.P. where she was Director of Risk Management for four years. Prior to joining industry, Dr. Smith held faculty appointments at New York University, Memorial-Sloan Kettering Cancer Center, and Mount Sinai School of Medicine where she was principal investigator on research studies examining psychosocial adjustment, quality of life outcomes, healthcare utilization, and doctor-patient com-munication in cancer and HIV patients with funding from the American Cancer Society, NIH, AHRQ, and the Susan B. Komen Breast Cancer Foundation. Dr. Smith holds a doctorate in health services research from the Robert Wagner School of Public Service, New York University. Prior to receiving her doctorate Dr. Smith worked at the federal Centers for Disease Control and Prevention and the New York City Health Department.",

year = "2010",

month = jun,

doi = "10.3109/10826081003682107",

language = "English",

volume = "45",

pages = "1509--1524",

journal = "Substance Use and Misuse",

issn = "1082-6084",

publisher = "Informa Healthcare",

number = "10",

}

TY - JOUR

T1 - Validity of self-reported misuse of prescription opioid analgesics

AU - Smith, Meredith

AU - Rosenblum, Andrew

AU - Parrino, Mark

AU - Fong, Chunki

AU - Colucci, Salvatore

N1 - Funding Information: Meredith Smith is Senior Scientific Director, Risk Man-agement for Pain Care and Immunology Development at Abbott Laboratories. Previously, Dr. Smith was at Purdue Pharma L.P. where she was Director of Risk Management for four years. Prior to joining industry, Dr. Smith held faculty appointments at New York University, Memorial-Sloan Kettering Cancer Center, and Mount Sinai School of Medicine where she was principal investigator on research studies examining psychosocial adjustment, quality of life outcomes, healthcare utilization, and doctor-patient com-munication in cancer and HIV patients with funding from the American Cancer Society, NIH, AHRQ, and the Susan B. Komen Breast Cancer Foundation. Dr. Smith holds a doctorate in health services research from the Robert Wagner School of Public Service, New York University. Prior to receiving her doctorate Dr. Smith worked at the federal Centers for Disease Control and Prevention and the New York City Health Department.

PY - 2010/6

Y1 - 2010/6

N2 - Aim: To determine concurrent validity of self-reported misuse of prescription opioids. Design and Setting: Cross-sectional study in five U.S. methadone maintenance programs. Participants: 92 addicts. Measurements: Self-reported questionnaire assessing past-month misuse of 14 opioid analgesics, and color photographs of five opioid analgesics with instructions to mark those used in the past month "to get high." Concordance between self-report and photograph endorsement was assessed via Kappa statistic. Findings: 29 respondents completed both questionnaire and photograph endorsements. Kappas were 0.62 (OxyContin®), 0.59 (methadone), 0.49 (Dilaudid®), and 0.46 (generic extended-release oxycodone). Conclusions: Good-to-fair concurrent validity of self-reported abuse was seen for OxyContin®, methadone, Dilaudid®, and generic extended-release oxycodone.

AB - Aim: To determine concurrent validity of self-reported misuse of prescription opioids. Design and Setting: Cross-sectional study in five U.S. methadone maintenance programs. Participants: 92 addicts. Measurements: Self-reported questionnaire assessing past-month misuse of 14 opioid analgesics, and color photographs of five opioid analgesics with instructions to mark those used in the past month "to get high." Concordance between self-report and photograph endorsement was assessed via Kappa statistic. Findings: 29 respondents completed both questionnaire and photograph endorsements. Kappas were 0.62 (OxyContin®), 0.59 (methadone), 0.49 (Dilaudid®), and 0.46 (generic extended-release oxycodone). Conclusions: Good-to-fair concurrent validity of self-reported abuse was seen for OxyContin®, methadone, Dilaudid®, and generic extended-release oxycodone.

KW - Dilaudid®

KW - Opioid analgesic abuse

KW - OxyContin®

KW - Self-reported drug misuse

KW - Validity

UR - https://www.scopus.com/pages/publications/77954230425

U2 - 10.3109/10826081003682107

DO - 10.3109/10826081003682107

M3 - Article

C2 - 20590372

AN - SCOPUS:77954230425

SN - 1082-6084

VL - 45

SP - 1509

EP - 1524

JO - Substance Use and Misuse

JF - Substance Use and Misuse

IS - 10

ER -

Validity of self-reported misuse of prescription opioid analgesics

Abstract

Keywords

Access to Document

Fingerprint

Cite this